Evaluate high-risk patient populations for PNH.
Early diagnosis drives effective PNH management
Diverse PNH symptomatology may complicate and delay diagnosis. Disease progression resulting from serious clinical sequelae reinforces the importance of early diagnosis. Accordingly, the current availability of an effective PNH treatment option warrants testing appropriate patients. Click below to learn more about the PNH Diagnostic Pathway for high-risk patients, including those with aplastic anemia, myelodysplastic syndromes, and unexplained thromboses.

References: 1. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.